Stockscreener 앱 받기
24.28
2.75%
0.65
시장 영업 전:
23.71
-0.57
-2.35%
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board - Endpoints News
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Price, News & Analysis - kalkine.ca
Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX) - Yahoo Finance
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results - webull.com
Bicara Therapeutics CEO Claire Mazumdar Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Bicara Therapeutics CFO Ivan Hyep Executes Sale of 12,500 Shares via 10b5-1 Plan - Kalkine Media
Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock - MarketBeat
Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics (BCAX) CFO exercises options, sells 12,500 shares under 10b5-1 plan - Stock Titan
Bicara Therapeutics (BCAX) CEO exercises 10K options and sells 10K shares under plan - Stock Titan
Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares - Stock Titan
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds (NASDAQ:BCAX) - Seeking Alpha
BCAX Maintained by Wells Fargo -- Price Target Raised to $23.00 - GuruFocus
Wells Fargo & Company Boosts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $23.00 - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning - Investing.com
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning By Investing.com - Investing.com Nigeria
BCAX SWOT Analysis: Financial Losses Highlighted in 10-Q Filing - GuruFocus
Bicara Therapeutics announces CEO transition, CFO appointment By Investing.com - Investing.com UK
Bicara Therapeutics stock price target raised to $39 by BTIG - Investing.com Australia
Bicara Therapeutics Inc. Stock 12‑Month Price Target Raised to $32.46, Implies 17% Upside - TradingView
Bicara Therapeutics (BCAX) deepens R&D investment while holding $497M in cash - Stock Titan
Bicara Therapeutics Inc. 2026: Revenue ($55.76M), Net income ($55.44M), EPS ($0.82) — 10-Q Summary - TradingView
Bicara Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Morgan Stanley raises Bicara Therapeutics stock price target on cash runway - Investing.com
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says - marketscreener.com
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Yahoo Finance
Bicara Q2 2026 slides: leadership shift amid rising spend By Investing.com - Investing.com Canada
Mizuho Securities Adjusts Bicara Therapeutics PT to $20 From $18, Maintains Neutral Rating - marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownHere's Why - MarketBeat
Transcript : Bicara Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Form 8K Bicara Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Wedbush Adjusts PT on Bicara Therapeutics to $33 From $30, Keeps Outperform Rating - marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Posts Earnings Results, Hits Expectations - MarketBeat
BCAX: Leadership transitions and strong FICERA data drive momentum toward commercialization and growth - TradingView
Bicara Therapeutics Q2 EPS of $(0.82) beats estimates - scanx.trade
Earnings call transcript: Bicara Therapeutics posts Q2 2026 loss as shares fall 16.7% - Investing.com
Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances - Yahoo Finance
Bicara Therapeutics Q2 Earnings Call Highlights - MarketBeat
Bicara Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bicara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Bicara Therapeutics Appoints Ryan Cohlhepp As President & CEO Effective January 2027 - TradingView
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth - Sahm
Bicara Therapeutics stock gains 3% on pivotal trial enrollment progress By Investing.com - Investing.com Canada
Bicara Therapeutics announces CEO transition, CFO appointment - Investing.com
0.52%
0.07%
자본화:
|
볼륨(24시간):